We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
-1.31%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$15.3B
AUM Growth
-$2.36B
Cap. Flow
-$405M
Cap. Flow %
-2.65%
Top 10 Hldgs %
84.69%
Holding
128
New
12
Increased
7
Reduced
17
Closed
13

Top Buys

Rank Stock Value
1
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$36M
2
AKRO
Akero Therapeutics
AKRO
+$34.4M
3
VERU icon
Veru
VERU
+$23.2M
4
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$22.8M
5
IDYA icon
IDEAYA Biosciences
IDYA
+$21.7M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$311M
2
INSM icon
Insmed
INSM
+$51.2M
3
LEGN icon
Legend Biotech
LEGN
+$47.1M
4
KRYS icon
Krystal Biotech
KRYS
+$27.9M
5
PACB icon
Pacific Biosciences
PACB
+$24.8M

Sector Composition

Rank Sector Weight
1 Healthcare 98.96%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DNLI icon
51
Denali Therapeutics
DNLI
$3.78B
$18.1M 0.12%
588,738
– –
OPT
52
DELISTED
Opthea Limited American Depositary Shares
OPT
$16.7M 0.11%
2,691,391
-4,800
-0.2% -$30.8K
BLUE
53
DELISTED
bluebird bio
BLUE
$15.8M 0.1%
124,986
– –
CRNX icon
54
Crinetics Pharmaceuticals
CRNX
$8.88B
$14.4M 0.09%
735,716
-91,764
-11% -$1.87M
WHWK
55
Whitehawk Therapeutics
WHWK
$181M
$14M 0.09%
+989,928
New +$13M
TCDA
56
DELISTED
Tricida, Inc. Common Stock
TCDA
$13.8M 0.09%
1,320,290
-182,800
-12% -$2M
AFMD
57
DELISTED
Affimed
AFMD
$13.6M 0.09%
659,683
– –
DICE
58
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$11.9M 0.08%
588,235
– –
ANAB icon
59
AnaptysBio
ANAB
$1.55B
$10.9M 0.07%
427,179
– –
KYNB
60
Kyntra Bio
KYNB
$27.7M
$10.6M 0.07%
32,629
– –
ADAP
61
DELISTED
Adaptimmune Therapeutics
ADAP
$10.6M 0.07%
9,830,877
– –
ZYME icon
62
Zymeworks
ZYME
$1.62B
$10.5M 0.07%
1,708,472
– –
PNT
63
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$9.04M 0.06%
+1,169,103
New +$9.92M
TCRX icon
64
TScan Therapeutics
TCRX
$48.5M
$8.49M 0.06%
2,784,792
– –
CBAY
65
DELISTED
Cymabay Therapeutics
CBAY
$7.6M 0.05%
2,170,464
– –
VERA icon
66
Vera Therapeutics
VERA
$2.33B
$7.1M 0.05%
333,333
– –
PACB icon
67
Pacific Biosciences
PACB
$438M
$6.55M 0.04%
1,127,782
-4,317,181
-79% -$24.8M
FLGT icon
68
Fulgent Genetics
FLGT
$558M
$6.35M 0.04%
166,619
-34,825
-17% -$1.75M
AMRN
69
Amarin Corp
AMRN
$298M
$5.86M 0.04%
268,856
-789,634
-75% -$21.2M
ACHL
70
DELISTED
Achilles Therapeutics
ACHL
$5.86M 0.04%
2,591,366
– –
VOR icon
71
Vor Biopharma
VOR
$1.06B
$5.83M 0.04%
73,296
+16,358
+29% +$1.61M
RETA
72
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$5.63M 0.04%
223,976
– –
BCEL
73
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$5.55M 0.04%
3,532,760
– –
NKTX icon
74
Nkarta
NKTX
$152M
$5.26M 0.03%
400,000
– –
TLIS
75
DELISTED
Talis Biomedical Corporation Common Stock
TLIS
$5.2M 0.03%
508,322
– –
1 2
3
4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q3 2022 Portfolio in Review

As of Q3 2022, Baker Bros. Advisors held 128 positions worth $15.3B, down 13% from $17.6B the previous quarter. Its ten largest holdings account for 85% of the portfolio.

Baker Bros. Advisors's Q3 2022 filing shows 12 new, 7 increased, 17 reduced and 13 closed positions. Its largest new stake was Veru: 160,958 shares worth $18.5M. The largest sale was argenx, an estimated $311M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q3 2022 buy was Veru: 160,958 shares worth $18.5M.
  • Baker Bros. Advisors added most to Rhythm Pharmaceuticals in Q3 2022, an estimated $36M increase.
  • Baker Bros. Advisors's biggest Q3 2022 reduction was argenx, cutting an estimated $311M.
  • Baker Bros. Advisors fully exited Legend Biotech in Q3 2022, selling an estimated $47.1M.
  • Baker Bros. Advisors's ten largest holdings make up 85% of its $15.3B portfolio in Q3 2022.
  • Baker Bros. Advisors opened 12 new positions and closed 13 in Q3 2022.
  • Baker Bros. Advisors's portfolio value fell 13% quarter-over-quarter to $15.3B.

Based on Baker Bros. Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.